Building Biotech Technology Transfer Opportunities: Sponsor and developer strategies for success

Published by	Business Insights
Published	February, 2010	Product code	114753
Content info	137 pages
Price	US $ 3835 PDF by E-mail (Single User License) US $ 14382 PDF by E-mail (Global Site License)

Introduction
Related Reports

Building Biotech Technology Transfer Opportunities: Sponsor and developer strategies for success published by Business Insights in February, 2010. This report consists of 137 pages and the price starts from US $ 3835.

Introduction

Abstract

Drug developers have long been under pressure to introduce new products in an environment of escalating R&D costs, blockbuster patent expiration and resulting generic competition. Current weak economic conditions have exacerbated these challenges with sweeping R&D staff and budget reductions. In order to remain competitive, drug makers must now do more with less. Technology transfer, particularly of new biotechnologies that offer novel means to address unmet medical needs, offer a way to cost effectively address these challenges. They also provide technology developers with a mechanism to monetize their inventions. However, while some drug makers and technology developers have optimized their biotech tech transfer methodologies and have developed sophisticated processes to select, monitor and manage a wide range of relationships, many other biotech tech transfer projects fail. A large proportion of these failures could be averted as many of the most common reasons for failure are preventable problems relating to due diligence failures, shortcomings in deal structure, management changes, cultural challenges, and inappropriate project organization and expectations. This report provides details on how to avoid these common pitfalls with case studies that illustrate best practices.

Executive Summary

Overview of biotech tech transfer
Why biotech tech transfer deals fail
Strategies to ensure successful biotech tech transfer deals
The future of biotech tech transfer deals

Chapter 1 Overview of biotech tech transfer

Summary
The biotechnology industry today
- Biotechnology technologies and techniques
  - Proliferation of investigational products
- Funding issues
  - Need to partner to advance product development
- The emergence of biotechnology brokers
Drug development challenges
- More complicated disease targets
- Escalating costs
- Increased regulatory scrutiny
- Diminished in-house R&D resources
Types of biotech tech transfer relationships
- Academic R&D infusions
- Biotech biotech deals
- Pharma biotech alliances
  - Licensing
  - R&D collaborations
  - Sales, distribution and co-marketing agreements
  - Joint ventures
  - Acquisitions
Volume of recent deals
Relationship trends
- Volume and value
- Ownership
Conclusion

Chapter 2 Why biotech tech transfer deals fail

Summary
High failure rates
- Symptoms of deal failure
- Factors that do not affect deal failure
Implications of deal failure
- Impact on technology developers
- Impact on technology sponsors
- Lost value of failed deals
Main causes of biotech tech transfer failure
- Due diligence failures
  - Technology performance
  - Patent issues
  - Developer organization strength
- Deal structure
  - Financial compensation
- Management changes
- Cultural differences
- Project organization and expectations
- Other preventable problems
- Technology failure
Conclusion

Chapter 3 Strategies to ensure successful biotech tech transfer deals

Summary
Measures of success
- Success for the technology developer
- Success for the technology sponsor
Key biotech tech transfer strategies
- Strategies for both technology developers and sponsors
  - Meeting technology challenges
- Strategies for technology developers
  - Optimizing resources
  - Thinking like a customer
  - Working with professional tech transfer organizations
  - Prolific publishing
- Strategies for technology sponsors
  - Thorough technology identification and due diligence
  - Structuring innovative deal terms
  - Addressing compensation issues
  - Fostering an entrepreneurial developer environment
  - Ensuring effective alliance management
  - Navigating cultural chasms
  - Addressing international intellectual property challenges
Conclusion

Chapter 4 The future of biotech tech transfer deals

Summary
Introduction
The future of drug development
- Impact of the economy
- US healthcare reform
- Biosimilars
Biotechnology in 2010 - 2015
- Where biotech fits into Big Pharma
- Dedicated biotechnology companies
Biotech tech transfer deal trends 2010 - 2015
- Volume and value
- Ownership
- Intellectual property issues
- Success rates
Conclusion

Index

List of Figures

Figure 1.1: Frequency of biotech tech transfer deals by type of institution
Figure 1.2: Number and volume of biopartnering deals, 1997 - 2009
Figure 1.3: Acquisitions as a proportion of biotech tech transfer deals,
Figure 2.4: Characteristics of biotech tech transfer failure causes
Figure 2.5: Relative importance to sponsor of technology developer
Figure 3.6: Strategies to optimize biotech tech transfer opportunities
Figure 4.7: Biopharmaceutical vs. other pharmaceutical sales, 2009 - 2015
Figure 4.8: Impact of industry and economic trends on conventional and biotech drug developers, 2009 - 2015
Figure 4.9: Relative importance of biotechnology for leading pharmaceutical companies, 2009 2015
Figure 4.10: Number and average size of global biotech companies, 2009 - 2015
Figure 4.11: Number and volume of biopartnering deals, 2009 - 2015

List of Tables

Table 1.1: Definition of biotechnology techniques
Table 1.2: Biotech tech transfer deals, 2009
Table 1.3: Biotech tech transfer deals, 2009 (Contd.)
Table 1.4: Biotech tech transfer deals, 2009 (Contd.)
Table 1.5: Biotech tech transfer deals, 2009 (Contd.)
Table 1.6: Biotech tech transfer deals, 2009 (Contd.)
Table 1.7: Biotech tech transfer deals, 2009 (Contd.)
Table 1.8: Biotech tech transfer deals, 2009 (Contd.)
Table 1.9: Biotech tech transfer deals, 2009 (Contd.)
Table 1.10: Biotech tech transfer deals, 2009 (Contd.)
Table 1.11: Biotech tech transfer deals, 2009 (Contd.)
Table 1.12: Biotech tech transfer deals, 2009 (Contd.)
Table 1.13: Biotech tech transfer deals, 2009 (Contd.)
Table 1.14: Biotech tech transfer deals, 2009 (Contd.)
Table 1.15: Biotech tech transfer deals, 2009 (Contd.)
Table 1.16: Biotech tech transfer deals, 2009 (Contd.)
Table 3.17: Technology transfer areas of interest for Merck & Co., 2010
Table 3.18: Technology transfer areas of interest for Merck & Co., 2010 (Contd.)
Table 3.19: Novartis private equity fund holdings, 2010
Table 3.20: Novartis private equity fund holdings, 2010 (Contd.)
Table 3.21: Novartis private equity fund holdings, 2010 (Contd.)
Table 3.22: Novartis private equity fund holdings, 2010 (Contd.)
Table 4.23: Millions of older and overweight persons in the US and EU, 2009 - 2015
Table 4.24: Biosimilars approved in the US and EU, 2010